{"transactions":[{"id":4622459,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T01:30:04.000Z","date":"2026-09-16","kind":"purchase","planned":false,"acquired":true,"shares":53000,"price":1.92,"value":101760.0,"ownership":{"direct":true},"balance_after":55274,"source":{"system":"sec-edgar","filing":"0001193125-26-394831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704234/000119312526394831/ownership.xml","form_type":"4"}},{"id":940537,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T01:03:44.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":13.3,"exercise_date":"2027-01-09","expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001704234-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000170423426000001/primary_doc.xml","form_type":"4"}},{"id":1093928,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T12:12:14.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80000,"derivative":{"exercise_price":5.75,"exercise_date":"2025-07-01","expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001654954-25-007737","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007737/section16.xml","form_type":"4"}},{"id":1334917,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T00:58:31.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-24-015473","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015473/section16.xml","form_type":"4"}},{"id":2187696,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-08-12T20:24:03.000Z","date":"2022-08-11","kind":"gift","acquired":true,"shares":567871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issuer's shares held in a grantor retained annuity trust (the \"GRAT\") were distributed to the reporting person upon termination of the GRAT and in satisfaction of an annuity due to the reporting person."}],"balance_after":3637871,"source":{"system":"sec-edgar","filing":"0001654954-22-011198","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422011198/section16.xml","form_type":"4"}},{"id":2187695,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-08-12T20:24:03.000Z","date":"2022-08-11","kind":"gift","acquired":false,"shares":567871,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Declan Doogan 2021 GRAT DTD 03-04-2021"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issuer's shares held in a grantor retained annuity trust (the \"GRAT\") were distributed to the reporting person upon termination of the GRAT and in satisfaction of an annuity due to the reporting person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person's wife, Dorothy Doogan, is the trustee of the GRAT."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001654954-22-011198","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422011198/section16.xml","form_type":"4"}},{"id":2237058,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T01:08:41.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":0.62,"exercise_date":"2023-06-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-22-008235","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008235/section16.xml","form_type":"4"}},{"id":2401728,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-11-30","kind":"gift","acquired":true,"shares":5475,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":632987,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401727,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-11-30","kind":"gift","acquired":false,"shares":5475,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401726,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-11-22","kind":"gift","acquired":true,"shares":491260,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":627512,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401725,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-11-22","kind":"gift","acquired":false,"shares":491260,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5475,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401724,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-10-14","kind":"gift","acquired":true,"shares":7342,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan Revocable Trust"},"balance_after":7342,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401723,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-10-14","kind":"gift","acquired":false,"shares":7342,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan 2020 Trust"},"balance_after":180318,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401722,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-10-14","kind":"gift","acquired":true,"shares":7015,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":136252,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401721,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-10-14","kind":"gift","acquired":false,"shares":7015,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan 2021 Trust"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401720,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-21","kind":"gift","acquired":false,"shares":20800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan Revocable Trust"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401719,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-21","kind":"other","acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan 2020 Trust"},"balance_after":187660,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401718,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-21","kind":"gift","acquired":true,"shares":20800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":129237,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401717,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-21","kind":"other","acquired":false,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":108437,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401716,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-18","kind":"gift","acquired":false,"shares":31540,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan Revocable Trust"},"balance_after":20800,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401715,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-18","kind":"gift","acquired":true,"shares":20800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan Revocable Trust"},"balance_after":52340,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401714,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-18","kind":"gift","acquired":false,"shares":20800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan 2020 Trust"},"balance_after":17660,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401713,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-18","kind":"gift","acquired":true,"shares":31540,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":278437,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401712,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-18","kind":"gift","acquired":true,"shares":113912,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":246897,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401711,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-05-18","kind":"gift","acquired":false,"shares":113912,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":496735,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401710,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-24","kind":"gift","acquired":true,"shares":132901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":132985,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401709,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-24","kind":"gift","acquired":false,"shares":132901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan 2021 Trust"},"balance_after":7015,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401708,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-22","kind":"gift","acquired":true,"shares":22315,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan Revocable Trust"},"balance_after":31540,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401707,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-22","kind":"gift","acquired":false,"shares":22315,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan 2020 Trust"},"balance_after":38460,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401706,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-18","kind":"gift","acquired":false,"shares":139916,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":84,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401705,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-18","kind":"gift","acquired":true,"shares":139916,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan 2021 Trust"},"balance_after":139916,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401704,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-16","kind":"gift","acquired":false,"shares":60775,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan Revocable Trust"},"balance_after":9225,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401703,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-16","kind":"gift","acquired":true,"shares":60775,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan 2020 Trust"},"balance_after":60775,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401702,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-08","kind":"gift","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Dorothy Doogan Revocable Trust"},"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401701,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-08","kind":"gift","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Declan Doogan Revocable Trust"},"balance_after":140000,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401700,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:44:02.000Z","date":"2021-03-08","kind":"gift","acquired":false,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":610647,"source":{"system":"sec-edgar","filing":"0001562180-22-001436","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001436/primarydocument.xml","form_type":"5"}},{"id":2401699,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:41:28.000Z","date":"2020-06-16","kind":"sale","acquired":false,"shares":10000,"price":68.97,"value":689700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.77 - $69.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing."}],"balance_after":323912,"source":{"system":"sec-edgar","filing":"0001562180-22-001435","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001435/primarydocument.xml","form_type":"4/A","original_submission_date":"2020-06-17"}},{"id":2401698,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:41:28.000Z","date":"2020-06-16","kind":"sale","acquired":false,"shares":15508,"price":68.5828,"value":1063582.0624,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 - $68.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing."}],"balance_after":676002,"source":{"system":"sec-edgar","filing":"0001562180-22-001435","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001435/primarydocument.xml","form_type":"4/A","original_submission_date":"2020-06-17"}},{"id":2401697,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:41:28.000Z","date":"2020-06-15","kind":"sale","acquired":false,"shares":13334,"price":68.1523,"value":908742.7682,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.86 - $68.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing."}],"balance_after":333912,"source":{"system":"sec-edgar","filing":"0001562180-22-001435","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001435/primarydocument.xml","form_type":"4/A","original_submission_date":"2020-06-17"}},{"id":2401696,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:41:28.000Z","date":"2020-06-15","kind":"sale","acquired":false,"shares":2464,"price":67.8274,"value":167126.7136,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 - $67.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing."}],"balance_after":726002,"source":{"system":"sec-edgar","filing":"0001562180-22-001435","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001435/primarydocument.xml","form_type":"4/A","original_submission_date":"2020-06-17"}},{"id":2401691,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:40:41.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":13334,"price":66.0053,"value":880114.6702,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.79 - $66.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing."}],"balance_after":347246,"source":{"system":"sec-edgar","filing":"0001562180-22-001434","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001434/primarydocument.xml","form_type":"4/A","original_submission_date":"2020-06-12"}},{"id":2401690,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:40:41.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":12580,"price":65.5513,"value":824635.354,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 - $65.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing."}],"balance_after":792669,"source":{"system":"sec-edgar","filing":"0001562180-22-001434","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001434/primarydocument.xml","form_type":"4/A","original_submission_date":"2020-06-12"}},{"id":2401689,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:40:41.000Z","date":"2020-06-11","kind":"sale","acquired":false,"shares":13333,"price":64.7077,"value":862747.7641,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.54 - $65.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing."}],"balance_after":360580,"source":{"system":"sec-edgar","filing":"0001562180-22-001434","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001434/primarydocument.xml","form_type":"4/A","original_submission_date":"2020-06-12"}},{"id":2401688,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-02-11T21:40:41.000Z","date":"2020-06-11","kind":"sale","acquired":false,"shares":11706,"price":64.4221,"value":754125.1026,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 - $64.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing."}],"balance_after":859335,"source":{"system":"sec-edgar","filing":"0001562180-22-001434","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022001434/primarydocument.xml","form_type":"4/A","original_submission_date":"2020-06-12"}},{"id":2490607,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-12-01T19:24:41.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":11499,"price":113.2547,"value":1302315.7953,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.92 - $113.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":870648,"source":{"system":"sec-edgar","filing":"0001562180-21-007370","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007370/primarydocument.xml","form_type":"4"}},{"id":2490606,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-12-01T19:24:41.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":13026,"price":112.3996,"value":1464117.1896,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.92 - $112.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":882147,"source":{"system":"sec-edgar","filing":"0001562180-21-007370","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007370/primarydocument.xml","form_type":"4"}},{"id":2507470,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":47.1,"exercise_date":"2021-04-30","expiration_date":"2030-04-29","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507469,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying this option vested as to 25% of the shares on April 6, 2017, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date."}],"balance_after":0,"derivative":{"exercise_price":10.82,"expiration_date":"2027-04-05","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507468,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":61.76,"exercise_date":"2020-04-30","expiration_date":"2029-05-20","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507467,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":28.76,"exercise_date":"2019-05-01","expiration_date":"2028-04-30","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507466,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this option vested as to 25% of the shares on December 15, 2016, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date."}],"balance_after":0,"derivative":{"exercise_price":9.29,"expiration_date":"2026-12-14","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507465,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vested as to 25% of the shares on October 23, 2015, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date."}],"balance_after":0,"derivative":{"exercise_price":5.6,"expiration_date":"2025-10-22","underlying":"Common Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507464,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option vested as to 25% of the shares on November 26, 2014, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date."}],"balance_after":0,"derivative":{"exercise_price":0.61,"expiration_date":"2024-11-25","underlying":"Common Shares","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507463,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":7073,"price":117.8724,"value":833711.4852,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.33 - $118.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":895173,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507462,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":18230,"price":116.6853,"value":2127173.019,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.32 - $117.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":902246,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507461,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":12437,"price":115.9042,"value":1441500.5354,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.31 - $116.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":920476,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507460,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":18000,"price":47.1,"value":847800.0,"ownership":{"direct":true},"balance_after":932913,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507459,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":30000,"price":10.82,"value":324600.0,"ownership":{"direct":true},"balance_after":914913,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507458,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":18000,"price":61.76,"value":1111680.0,"ownership":{"direct":true},"balance_after":884913,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507457,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":18000,"price":28.76,"value":517680.0,"ownership":{"direct":true},"balance_after":866913,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507456,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":50000,"price":9.29,"value":464500.0,"ownership":{"direct":true},"balance_after":848913,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507455,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":175000,"price":5.6,"value":980000.0,"ownership":{"direct":true},"balance_after":798913,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2507454,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-11-17T19:03:42.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":250000,"price":0.61,"value":152500.0,"ownership":{"direct":true},"balance_after":623913,"source":{"system":"sec-edgar","filing":"0001562180-21-007138","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007138/primarydocument.xml","form_type":"4"}},{"id":2607920,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-08-11T20:30:50.000Z","date":"2021-06-30","kind":"gift","acquired":false,"shares":567871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction represents a gift from Dr. Doogan to fund the Declan Doogan 2021 GRAT DTD 03-04-2021 (the \"Trust\").  Dr. Doogan's wife, Dorothy Doogan, is the trustee of the Trust.  Per the terms of the Trust, during its term the Trust must make annuity payments to Dr. Doogan which will be accomplished by transferring shares of common stock back to Dr. Doogan"}],"balance_after":2502129,"source":{"system":"sec-edgar","filing":"0001654954-21-008766","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421008766/section16.xml","form_type":"4"}},{"id":2669470,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2021-06-15T20:34:24.000Z","date":"2021-06-11","kind":"exercise","acquired":false,"shares":3070,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."}],"balance_after":0,"derivative":{"exercise_date":"2021-06-11","expiration_date":"2021-06-11","underlying":"Common Stock","underlying_shares":3070000},"source":{"system":"sec-edgar","filing":"0001654954-21-006925","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006925/section16.xml","form_type":"4"}},{"id":2669469,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T20:34:24.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6250,"derivative":{"exercise_price":2,"exercise_date":"2022-06-10","expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001654954-21-006925","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006925/section16.xml","form_type":"4"}},{"id":2669468,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-15T20:34:24.000Z","date":"2021-06-11","kind":"exercise","acquired":true,"shares":3070000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."}],"balance_after":3637871,"source":{"system":"sec-edgar","filing":"0001654954-21-006925","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006925/section16.xml","form_type":"4"}},{"id":2723212,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-07T16:34:03.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":11996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2022 or (b) the date of the 2022 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date."}],"balance_after":11996,"derivative":{"exercise_price":71.94,"expiration_date":"2031-05-04","underlying":"Common Shares","underlying_shares":11996},"source":{"system":"sec-edgar","filing":"0001562180-21-003336","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021003336/primarydocument.xml","form_type":"4"}},{"id":3107238,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-17T21:55:14.000Z","date":"2020-06-16","kind":"sale","acquired":false,"shares":300,"price":69.4167,"value":20825.01,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.39 - $69.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":626002,"source":{"system":"sec-edgar","filing":"0001562180-20-004574","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004574/primarydocument.xml","form_type":"4"}},{"id":3107237,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-17T21:55:14.000Z","date":"2020-06-16","kind":"sale","acquired":false,"shares":25208,"price":68.7265,"value":1732457.612,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 - $69.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":626302,"source":{"system":"sec-edgar","filing":"0001562180-20-004574","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004574/primarydocument.xml","form_type":"4"}},{"id":3107236,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-17T21:55:14.000Z","date":"2020-06-16","kind":"sale","acquired":false,"shares":31920,"price":67.9046,"value":2167514.832,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.37 - $68.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":651510,"source":{"system":"sec-edgar","filing":"0001562180-20-004574","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004574/primarydocument.xml","form_type":"4"}},{"id":3107235,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-17T21:55:14.000Z","date":"2020-06-16","kind":"sale","acquired":false,"shares":2572,"price":66.9369,"value":172161.7068,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 - $67.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":683430,"source":{"system":"sec-edgar","filing":"0001562180-20-004574","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004574/primarydocument.xml","form_type":"4"}},{"id":3107234,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-17T21:55:14.000Z","date":"2020-06-15","kind":"sale","acquired":false,"shares":15797,"price":68.1016,"value":1075800.9752,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 - $68.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":686002,"source":{"system":"sec-edgar","filing":"0001562180-20-004574","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004574/primarydocument.xml","form_type":"4"}},{"id":3107233,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-17T21:55:14.000Z","date":"2020-06-15","kind":"sale","acquired":false,"shares":18703,"price":67.5056,"value":1262557.2368,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.78 - $67.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":701799,"source":{"system":"sec-edgar","filing":"0001562180-20-004574","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004574/primarydocument.xml","form_type":"4"}},{"id":3107232,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-17T21:55:14.000Z","date":"2020-06-15","kind":"sale","acquired":false,"shares":34336,"price":66.0494,"value":2267872.1984,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 - $68.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":720502,"source":{"system":"sec-edgar","filing":"0001562180-20-004574","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004574/primarydocument.xml","form_type":"4"}},{"id":3107231,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-17T21:55:14.000Z","date":"2020-06-15","kind":"sale","acquired":false,"shares":11164,"price":65.6181,"value":732560.4684,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.78 - $65.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":754838,"source":{"system":"sec-edgar","filing":"0001562180-20-004574","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004574/primarydocument.xml","form_type":"4"}},{"id":3111998,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-12T20:09:43.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":25914,"price":65.7849,"value":1704749.8986,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 - $66.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":766002,"source":{"system":"sec-edgar","filing":"0001562180-20-004471","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004471/primarydocument.xml","form_type":"4"}},{"id":3111997,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-12T20:09:43.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":28086,"price":64.7897,"value":1819683.5142,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.32 - $65.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":791916,"source":{"system":"sec-edgar","filing":"0001562180-20-004471","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004471/primarydocument.xml","form_type":"4"}},{"id":3111996,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-12T20:09:43.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":18400,"price":63.9004,"value":1175767.36,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.32 - $64.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":820002,"source":{"system":"sec-edgar","filing":"0001562180-20-004471","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004471/primarydocument.xml","form_type":"4"}},{"id":3111995,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-12T20:09:43.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":7600,"price":62.9279,"value":478252.04,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.32 - $62.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":838402,"source":{"system":"sec-edgar","filing":"0001562180-20-004471","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004471/primarydocument.xml","form_type":"4"}},{"id":3111994,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-12T20:09:43.000Z","date":"2020-06-11","kind":"sale","acquired":false,"shares":25039,"price":64.5742,"value":1616873.3938,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 - $65.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":846002,"source":{"system":"sec-edgar","filing":"0001562180-20-004471","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004471/primarydocument.xml","form_type":"4"}},{"id":3111993,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-12T20:09:43.000Z","date":"2020-06-11","kind":"sale","acquired":false,"shares":18474,"price":63.794,"value":1178530.356,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.31 - $64.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":871041,"source":{"system":"sec-edgar","filing":"0001562180-20-004471","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004471/primarydocument.xml","form_type":"4"}},{"id":3111992,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-12T20:09:43.000Z","date":"2020-06-11","kind":"sale","acquired":false,"shares":20043,"price":62.7754,"value":1258207.3422,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.31 - $63.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":889515,"source":{"system":"sec-edgar","filing":"0001562180-20-004471","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004471/primarydocument.xml","form_type":"4"}},{"id":3111991,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-06-12T20:09:43.000Z","date":"2020-06-11","kind":"sale","acquired":false,"shares":16444,"price":61.9672,"value":1018988.6368,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.31 - $62.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":909558,"source":{"system":"sec-edgar","filing":"0001562180-20-004471","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020004471/primarydocument.xml","form_type":"4"}},{"id":3165499,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-01T21:14:40.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2021 or (b) the date of the 2021 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date."}],"balance_after":18000,"derivative":{"exercise_price":47.1,"expiration_date":"2030-04-29","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001562180-20-003255","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020003255/primarydocument.xml","form_type":"4"}},{"id":3513550,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-23T18:33:43.000Z","date":"2019-05-21","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this stock option will vest in full on the earlier of (a) May 21, 2020 or (b) the date of the 2020 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date."}],"balance_after":18000,"derivative":{"exercise_price":61.76,"expiration_date":"2029-05-20","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-19-032463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119032463/doc4.xml","form_type":"4"}},{"id":3555059,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-04-16T19:23:40.000Z","date":"2019-04-16","kind":"sale","acquired":false,"shares":50000,"price":61.92,"value":3096000.0,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.89 - $62.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":926002,"source":{"system":"sec-edgar","filing":"0001209191-19-024835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119024835/doc4.xml","form_type":"4"}},{"id":3555058,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-04-16T19:23:40.000Z","date":"2019-04-12","kind":"sale","acquired":false,"shares":38825,"price":53.92,"value":2093444.0,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.66 - $54.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":976002,"source":{"system":"sec-edgar","filing":"0001209191-19-024835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119024835/doc4.xml","form_type":"4"}},{"id":3578483,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-03-26T18:30:18.000Z","date":"2019-03-26","kind":"sale","acquired":false,"shares":5824,"price":53.72,"value":312865.28,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.66 - $53.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":1014827,"source":{"system":"sec-edgar","filing":"0001209191-19-021354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119021354/doc4.xml","form_type":"4"}},{"id":3578482,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-03-26T18:30:18.000Z","date":"2019-03-22","kind":"sale","acquired":false,"shares":5351,"price":53.66,"value":287134.66,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":1020651,"source":{"system":"sec-edgar","filing":"0001209191-19-021354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119021354/doc4.xml","form_type":"4"}},{"id":3623317,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-03-01T17:59:11.000Z","date":"2019-03-01","kind":"sale","acquired":false,"shares":50000,"price":47.19,"value":2359500.0,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.01 - $47.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":1026002,"source":{"system":"sec-edgar","filing":"0001209191-19-015151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119015151/doc4.xml","form_type":"4"}},{"id":3623316,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-03-01T17:59:11.000Z","date":"2019-03-01","kind":"sale","acquired":false,"shares":595,"price":45.41,"value":27018.95,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":1076002,"source":{"system":"sec-edgar","filing":"0001209191-19-015151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119015151/doc4.xml","form_type":"4"}},{"id":3623315,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-03-01T17:59:11.000Z","date":"2019-02-27","kind":"sale","acquired":false,"shares":23384,"price":45.71,"value":1068882.64,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.41 - $46.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":1076597,"source":{"system":"sec-edgar","filing":"0001209191-19-015151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119015151/doc4.xml","form_type":"4"}},{"id":3623314,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-03-01T17:59:11.000Z","date":"2019-02-27","kind":"sale","acquired":false,"shares":1900,"price":45.86,"value":87134.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.75 - $46.045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":373913,"source":{"system":"sec-edgar","filing":"0001209191-19-015151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119015151/doc4.xml","form_type":"4"}},{"id":3623313,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-03-01T17:59:11.000Z","date":"2019-02-27","kind":"sale","acquired":false,"shares":18270,"price":45.25,"value":826717.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.75 - $45.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":375813,"source":{"system":"sec-edgar","filing":"0001209191-19-015151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119015151/doc4.xml","form_type":"4"}},{"id":3623312,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-03-01T17:59:11.000Z","date":"2019-02-27","kind":"sale","acquired":false,"shares":6875,"price":44.17,"value":303668.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.74 - $44.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":394083,"source":{"system":"sec-edgar","filing":"0001209191-19-015151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119015151/doc4.xml","form_type":"4"}},{"id":3632410,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-02-26T17:44:16.000Z","date":"2019-02-25","kind":"sale","acquired":false,"shares":13943,"price":45.49,"value":634267.07,"ownership":{"direct":false,"nature":"By the Declan Doogan 2014 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.41 - $46.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":1099981,"source":{"system":"sec-edgar","filing":"0001209191-19-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119013671/doc4.xml","form_type":"4"}},{"id":3632409,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-02-26T17:44:16.000Z","date":"2019-02-26","kind":"sale","acquired":false,"shares":100,"price":44.81,"value":4481.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":400958,"source":{"system":"sec-edgar","filing":"0001209191-19-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119013671/doc4.xml","form_type":"4"}},{"id":3632408,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-02-26T17:44:16.000Z","date":"2019-02-26","kind":"sale","acquired":false,"shares":20796,"price":44.31,"value":921470.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.79 - $44.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":401058,"source":{"system":"sec-edgar","filing":"0001209191-19-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119013671/doc4.xml","form_type":"4"}},{"id":3632407,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-02-26T17:44:16.000Z","date":"2019-02-25","kind":"sale","acquired":false,"shares":100,"price":45.74,"value":4574.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":421854,"source":{"system":"sec-edgar","filing":"0001209191-19-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119013671/doc4.xml","form_type":"4"}}],"next_cursor":"2019-02-26T17:44:16.000000Z,3632407"}